ALK
Positive Lung Cancer Treatment Market by Drugs (Crizotinib, Alectinib,
Ceritinib, and Brigatinib), by Distribution Channel (Hospital Pharmacies,
Retail Pharmacies, and Clinics), and by Geography (North America, Europe, Asia
Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and
Opportunity Analysis 2018 – 2026
ALK positive lung cancer
treatment is used for people suffering from lung cancer with Anaplastic
Lymphoma Kinase (ALK) mutation (the EML4-ALK fusion gene). This gene mutation
is due to gene rearrangement by fusion of two genes called as ALK and
Echinoderm Microtubule-associated protein Like 4 (EML4). The ALK gene fusion
was first reported in 2007, in Non-small cell lung cancer (NSCLC) patients.
ALK Positive Lung Cancer
Treatment Market Drivers
New drug approvals for treatment
of ALK positive lung cancer is expected to drive growth of the market. For
instance, in August 2018, China National Drug Administration (CNDA) approved
Alecensa (alectinib) of F. Hoffmann-La Roche Ltd., for treatment of ALK-positive
lung cancer. Moreover, CNDA granted marketing authorization for Alecensa
(alectinib), as monotherapy treatment for patients with anaplastic lymphoma
kinase (ALK)-positive and advanced non-small cell lung cancer (NSCLC).
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2201
ALK Positive Lung Cancer Treatment
Market Restraints
Development of rapid resistance
to drugs is expected to limit growth of the ALK positive lung cancer treatment
market. For instance, according to an Oncology Live February 2018 report, major
challenge in drug development is rapid growth in resistance, which is
responsible for slow patient recovery from disease. Moreover, according to an
article published in Cancers journal, in August 2017, the mechanisms for
resistance in drugs is tyrosine kinase mutations, and Epidermal Growth Factor
Receptor (EGFR) activation. These bypass mechanisms of resistance are
aggravating tumor cells, which in turn is restraining growth of the market.
ALK Positive Lung Cancer Treatment
Market – Regional Analysis
On the basis of region, the
global ALK positive lung cancer treatment market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North
America region is expected to witness significant growth in the market, owing
to increasing number of clinical trials operating in the U.S. For instance, TP
Therapeutics, Inc., is undergoing clinical trial for TPX-0005 drug for treating
ALK mutations. The study is expected to complete in December 2021.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/alk-positive-lung-cancer-treatment-market-2201
Asia Pacific region is expected
to witness the significant growth in the market, owing to increasing use of
tobacco and smoking leading to lung cancer.
According to an article published in Eastern Journal of medical Sciences
2017, lung cancer contributes around 6.8% of all cancers in India, representing
the significant burden of lung cancer on country, which is contributing towards
the cancer morbidity and mortality.
Key players operating in ALK
positive lung cancer treatment market include F. Hoffmann-La Roche Ltd., Pfizer
Inc., Novartis AG, TP Therapeutics, Inc., Bristol-Myers Squibb Company, and Eli
Lilly and Company.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2201
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment